| Levetiracetam |
20120085 |
Lyvam, Film coated tablet, 500, mg, Pack: 60 |
Alkaloid – INT d.o.o., Словения |
Alkaloid – INT d.o.o., Slandrova ulica 4 1231 Ljubljana-Crnuce,Словения |
49.46 |
9.89 |
59.35 |
4% |
1.98 |
51.44 |
10.29 |
61.73 |
16% |
7.91 |
59.35 |
11.87 |
71.22 |
цената се заличава HCР-396/03.07.2013 |
КЦРР-1567/05.11.2012 |
22.11.2012 |
22.11.2012 |
Заличен |
1422 |
| Levetiracetam |
20120087 |
Lyvam, Film coated tablet, 1000, mg, Pack: 60 |
Alkaloid – INT d.o.o., Словения |
Alkaloid – INT d.o.o., Slandrova ulica 4 1231 Ljubljana-Crnuce,Словения |
97.44 |
19.49 |
116.93 |
4% |
3.9 |
101.34 |
20.27 |
121.61 |
16% |
15.59 |
116.93 |
23.39 |
140.32 |
цената се заличава HCР-394/03.07.2013 |
КЦРР-1567/05.11.2012 |
22.11.2012 |
22.11.2012 |
Заличен |
1420 |
| Lixisenatide |
EU/1/12/811/003 |
Lyxumia, Solution for injection, 20 mcg – 3 ml, -, Pack: 2 pre-filled pens (dose 0.2 ml - 1 pen contains 14 doses) |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
114.26 |
22.85 |
137.11 |
4% |
4.57 |
118.83 |
23.77 |
142.6 |
16% |
18.28 |
137.11 |
27.42 |
164.53 |
|
НСР-8568/24.03.2016.; НСР-13094/06.07.2017; НСР-15133/02.03.2018; НСР-17136/01.11.2018 |
16.11.2018 |
02.12.2018 |
Активен |
3519 |
| Lixisenatide |
EU/1/12/811/003 |
Lyxumia, Solution for injection, 20 mcg – 3 ml, -, Pack: 2 pre-filled pens (dose 0.2 ml - 1 pen contains 14 doses) |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
114.75 |
22.95 |
137.7 |
4% |
4.59 |
119.34 |
23.87 |
143.21 |
16% |
18.36 |
137.7 |
27.54 |
165.24 |
|
НСР-8568/24.03.2016.; НСР-13094/06.07.2017; НСР-15133/02.03.2018 |
17.03.2018 |
02.04.2018 |
Неактивен |
3519 |
| Lixisenatide |
EU/1/12/811/003 |
Lyxumia, Solution for injection, 20 mcg – 3 ml, -, Pack: 2 pre-filled pens (dose 0.2 ml - 1 pen contains 14 doses) |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
115.84 |
23.17 |
139.01 |
4% |
4.63 |
120.47 |
24.09 |
144.56 |
16% |
18.53 |
139 |
27.8 |
166.8 |
|
НСР-8568/24.03.2016.; НСР-13094/06.07.2017 |
21.07.2017 |
02.08.2017 |
Неактивен |
3519 |
| Lixisenatide |
EU/1/12/811/003 |
Lyxumia, Solution for injection, 20 mcg – 3 ml, dose (0.2 ml) – 1 pen contains 14 doses, Pack: 2 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
117.17 |
23.43 |
140.6 |
4% |
4.69 |
121.86 |
24.37 |
146.23 |
16% |
18.75 |
140.61 |
28.12 |
168.73 |
|
НСР-8568/24.03.2016. |
08.04.2016 |
08.04.2016 |
Неактивен |
3519 |
| Lixisenatide |
EU/1/12/811/003 |
Lyxumia, Solution for injection, 20 mcg – 3 ml, dose (0.2 ml) – 1 pen contains 14 doses, Pack: 2 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
127.74 |
25.55 |
153.29 |
4% |
5.11 |
132.85 |
26.57 |
159.42 |
16% |
20.44 |
153.29 |
30.66 |
183.95 |
|
НСР-5460/16.01.2015 |
02.02.2015 |
02.02.2015 |
Неактивен |
3519 |
| Lixisenatide |
EU/1/12/811/003 |
Lyxumia, Solution for injection, 20 mcg – 3 ml, dose (0.2 ml) – 1 pen contains 14 doses, Pack: 2 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
147.37 |
29.47 |
176.84 |
4% |
5.89 |
153.26 |
30.65 |
183.91 |
16% |
23.58 |
176.84 |
35.37 |
212.21 |
корекц. решение НСР-5362/18.12.2014 |
НСР-3452/30.04.2014 |
|
|
Неактивен |
3519 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg - 3 ml, -, Pack: 1 pre-filled pen (dose 0.2 ml - 1 pen contains 14 doses) |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
62.59 |
12.52 |
75.11 |
4% |
2.5 |
65.09 |
13.02 |
78.11 |
16% |
10.01 |
75.1 |
15.02 |
90.12 |
НСР-16774/19.09.2018 (корекционно решение с предварително изпълнение) |
НСР-7301/29.10.2015; НСР-9719/07.07.2016 г.; НСР-16687/30.08.2018; НСР-19170/04.07.2019 |
19.07.2019 |
02.08.2019 |
Активен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg - 3 ml, -, Pack: 1 pre-filled pen (dose 0.2 ml - 1 pen contains 14 doses) |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
63.49 |
12.7 |
76.19 |
4% |
2.54 |
66.03 |
13.21 |
79.24 |
16% |
10.16 |
76.19 |
15.24 |
91.43 |
НСР-16774/19.09.2018 (корекционно решение с предварително изпълнение) |
НСР-7301/29.10.2015; НСР-9719/07.07.2016 г.; НСР-16687/30.08.2018 |
14.09.2018 |
02.10.2018 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg - 3 ml, -, Pack: 1 pre-filled pen (dose 0.2 ml - 1 pen contains 14 doses) |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
64.31 |
12.86 |
77.17 |
4% |
2.57 |
66.88 |
13.38 |
80.26 |
16% |
10.29 |
77.17 |
15.43 |
92.6 |
|
НСР-7301/29.10.2015; НСР-9719/07.07.2016 г. |
22.07.2016 |
02.08.2017 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg - 3 ml - 1 dose (0.2 ml) –, -, Pack: 1 pen contains 14 doses |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
64.31 |
12.86 |
77.17 |
4% |
2.57 |
66.88 |
13.38 |
80.26 |
16% |
10.29 |
77.17 |
15.43 |
92.6 |
|
НСР-7301/29.10.2015; НСР-9719/07.07.2016 г. |
02.08.2016 |
02.08.2016 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg – 3 ml, dose (0.2 ml) – 1 pen contains 14 doses, Pack: 1 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
65.27 |
13.05 |
78.32 |
4% |
2.61 |
67.88 |
13.58 |
81.46 |
16% |
10.44 |
78.32 |
15.66 |
93.98 |
|
НСР-7301/29.10.2015 |
14.11.2015 |
14.11.2015 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg – 3 ml, dose (0.2 ml) – 1 pen contains 14 doses, Pack: 1 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
65.83 |
13.17 |
79 |
4% |
2.63 |
68.46 |
13.69 |
82.15 |
16% |
10.53 |
78.99 |
15.8 |
94.79 |
|
НСР-5293/ 18.12.2014. |
01.01.2015 |
01.01.2015 |
Неактивен |
3468 |
| Lixisenatide |
EU/1/12/811/001 |
Lyxumia, Solution for injection, 10 mcg – 3 ml, dose (0.2 ml) – 1 pen contains 14 doses, Pack: 1 |
Sanofi-Aventis Groupe, Франция |
Sanofi-Aventis Deutschland GmbH, Германия |
73.7 |
14.74 |
88.44 |
4% |
2.95 |
76.65 |
15.33 |
91.98 |
16% |
11.79 |
88.44 |
17.69 |
106.13 |
корекц. решение НСР-5362/18.12.2014 |
НСР-3452/30.04.2014 |
|
|
Неактивен |
3468 |
| Alemtuzumab |
EU/1/01/193/002 |
Mabcampath, Concentrate for solution for infusion, 30, mg, Pack: 3 |
Genzyme Europe B.V., Нидерландия |
Bayer Schering Pharma AG, Germany |
2342.34 |
468.47 |
2810.81 |
4% |
10 |
2352.34 |
470.47 |
2822.81 |
16% |
25 |
2377.34 |
475.47 |
2852.81 |
цената се заличава КЦРР-1548/01.11.2012 |
КЦ-353/19.12.2008 |
22.01.2009 |
22.01.2009 |
Заличен |
361 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
649.77 |
129.95 |
779.72 |
4% |
10 |
659.77 |
131.95 |
791.72 |
16% |
25 |
684.77 |
136.95 |
821.72 |
промяна на обстоятелства НСР-15931/15.06.2018 |
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017; НСР-16587/24.08.2018 |
06.01.2018 |
02.10.2018 |
Активен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
649.77 |
129.95 |
779.72 |
4% |
10 |
659.77 |
131.95 |
791.72 |
16% |
25 |
684.77 |
136.95 |
821.72 |
промяна на обстоятелства НСР-15931/15.06.2018 |
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017; НСР-16587/24.08.2018 |
06.01.2018 |
02.10.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
649.77 |
129.95 |
779.72 |
4% |
10 |
659.77 |
131.95 |
791.72 |
16% |
25 |
684.77 |
136.95 |
821.72 |
промяна на обстоятелства НСР-15931/15.06.2018 |
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017; НСР-16587/24.08.2018 |
06.01.2018 |
02.10.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
804.39 |
160.88 |
965.27 |
4% |
10 |
814.39 |
162.88 |
977.27 |
16% |
25 |
839.39 |
167.88 |
1007.27 |
промяна на обстоятелства НСР-15931/15.06.2018 |
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017 |
06.01.2018 |
02.07.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG, Германия |
804.39 |
160.88 |
965.27 |
4% |
10 |
814.39 |
162.88 |
977.27 |
16% |
25 |
839.39 |
167.88 |
1007.27 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017 |
06.01.2018 |
02.02.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration GmbH, Германия |
Roche Pharma AG, Германия |
804.39 |
160.88 |
965.27 |
4% |
10 |
814.39 |
162.88 |
977.27 |
16% |
25 |
839.39 |
167.88 |
1007.27 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017 |
06.01.2018 |
02.02.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG, Германия |
804.39 |
160.88 |
965.27 |
4% |
10 |
814.39 |
162.88 |
977.27 |
16% |
25 |
839.39 |
167.88 |
1007.27 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017; НСР-14672/20.12.2017 |
06.01.2018 |
02.02.2018 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG, Германия |
806.41 |
161.28 |
967.69 |
4% |
10 |
816.41 |
163.28 |
979.69 |
16% |
25 |
841.41 |
168.28 |
1009.69 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017 |
18.04.2017 |
02.05.2017 |
Неактивен |
3833 |
| Rituximab |
EU/1/98/067/001 |
MabThera, Concentrate for solution for infusion, 100mg/10 ml, -, Pack: 2 vials |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG, Германия |
806.41 |
161.28 |
967.69 |
4% |
10 |
816.41 |
163.28 |
979.69 |
16% |
25 |
841.41 |
168.28 |
1009.69 |
|
НСР-6077/23.04.2015.; НСР-9705/07.07.2016г.; НСР-12209/03.04.2017 |
02.05.2017 |
02.05.2017 |
Неактивен |
3833 |